Delivered as a once-daily 30 mg/mL IV bolus injection over 15 seconds, Xifyrm can be used alone or alongside non-NSAID ...

Regulatory action was based on data from the Phase III IMforte trial, which showed that Zepzelca plus Tecentriq significantly ...

Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...

Ron Lanton, Partner, Lanton Law, discusses the constitutional and statutory challenges facing the President’s use of executive orders to implement international drug pricing models such as the Most ...

Phenomix Sciences published the results of a study conducted in partnership with the Mayo Clinic that tested the ...

The Lung Cancer Research Foundation is expanding its research advocate groups. The group is made up of lung cancer patients ...

Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...

Co-founder and CEO of CUTISS, Daniela Marino, PhD, talks about her switch from academia to the biotech industry and her 16-year journey developing a first-in-class personalized tissue therapy.

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma ...

Widaplik marks the first and only FDA-approved triple combination medication that can be used as an initial therapy for patients with hypertension who require multiple drugs to reach their blood ...

Ron Lanton, Partner, Lanton Law, outlines how the MFN executive order may face significant legal challenges from the pharmaceutical industry, citing concerns over due process, intellectual property, ...